| Disease |
Median OS |
1-year OS |
2-year OS |
5-year OS |
10-year OS
|
|---|
| Chordoma
|
| |
|
Overall (SEER data) |
6.3 years |
|
|
68% |
40%
|
| Glioma
|
| |
Low Grade (WHO II)
|
| |
|
RT alone (EORTC 22844) |
~6 years |
|
|
59% |
|
| |
|
RT alone (NCCTG) |
~9 years |
|
94% |
72% |
|
| |
|
Observation (EORTC 22845) |
7.4 years |
|
|
66% |
|
| |
High Grade (WHO III)
|
| |
|
RT alone (RTOG 9402) |
4.7 years |
|
|
46% |
|
| |
|
RT alone (EORTC 26951) |
3.4 years |
|
|
37% |
|
| |
High Grade (WHO IV)
|
| |
|
Observation (BTCG 69-01) |
3.2 months |
|
|
|
|
| |
|
RT alone (BTCG 69-01) |
8.1 months |
|
|
|
|
| Pancreas
|
| |
Resectable
|
| |
|
Surgery only (CONKO-001) |
1.7 years |
|
|
9% |
|
| |
|
Adjuvant 5FU/RT (GITSG 9173) |
1.7 years |
|
42% |
|
|
| |
|
Adjuvant 5FU/RT/Chemo (ESPAC-1) |
1.7 years |
|
|
|
|
| |
|
Adjuvant GEM-RT/5-FU/GEM (RTOG 9704) |
1.7 years |
|
|
|
|
| |
|
Adjuvant GEM (CONKO-001) |
1.9 years |
|
|
21% |
|
| |
Unresectable
|
| |
|
No treatment |
~4 months |
|
|
|
|
| |
|
Palliative bypass |
6-7 months |
|
|
|
|
| |
|
RT/5-FU (FFCD-SFRO) |
9 months |
32% |
|
|
|
| |
|
RT/GEM (ECOG E4201) |
11 months |
|
|
|
|
| |
|
GEM (FFCD-SFRO) |
13 months |
53% |
|
|
|
| |
|
RT/GEM (Taipei) |
14 months |
56% |
15% |
|
|
| |
|
RT/TNFerade(PACT) |
1.4 years |
71% |
|
|
|
| Prostate
|
| |
Early Stage (cT1-T2)
|
| |
|
Watchful waiting (SPCG-4) |
|
|
|
|
86%
|
| |
|
Surgery (SPCG-4) |
|
|
|
|
91%
|
| NSCLC
|
| |
Early Stage Operable
|
| |
|
Surgery (Stage I) composite |
|
|
|
65% |
|
| |
|
Surgery (Stage I) Brazil |
|
|
|
95% |
|
| |
|
Conventional RT (Stage I) composite |
|
|
|
20% |
|
| |
|
SBRT (Stage I) Japan |
|
|
|
83% |
|
| |
|
Surgery (Stage II) |
|
|
|
45% |
|
| Spinal Cord Compression
|
| |
|
RT Alone (Patchell) |
3 months
|
| |
|
Surgery + RT (Patchell) |
4 months
|
